Sun Pharma has acquired the rights to trademarks of diabetes drug Dapagliflozin under brands Oxra, Oxramet and Oxraduo in India from AstraZeneca AB, Sweden, parent company of AstraZeneca Pharma India with effect from May 28, 2021. The company has also taken a patent license to manufacture and commercialise Dapagliflozin and Dapagliflozin with Metformin combination in India from AstraZeneca AB with effect from May 28, 2021.
Consequently, AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016, for distribution of Dapagliflozin.
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.50 |
| Dr. Reddys Lab | 1221.45 |
| Cipla | 1230.00 |
| Zydus Lifesciences | 930.90 |
| Lupin | 2323.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: